Dyslipidemia - Pipeline Review, H2 2016

Choose Licence

 

Dyslipidemia - Pipeline Review, H2 2016 Summary Global Markets Directs, Dyslipidemia - Pipeline Review, H2 2016?, provides an overview of the Dyslipidemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyslipidemia and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Dyslipidemia - The report reviews pipeline therapeutics for Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Dyslipidemia therapeutics and enlists all their major and minor projects - The report assesses Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Dyslipidemia Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Dyslipidemia - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Dyslipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 Introduction 6 Dyslipidemia Overview 7 Therapeutics Development 8 Dyslipidemia - Therapeutics under Development by Companies 10 Dyslipidemia - Therapeutics under Investigation by Universities/Institutes 15 Dyslipidemia - Pipeline Products Glance 16 Dyslipidemia - Products under Development by Companies 20 Dyslipidemia - Products under Investigation by Universities/Institutes 28 Dyslipidemia - Companies Involved in Therapeutics Development 29 Dyslipidemia - Therapeutics Assessment 90 Drug Profiles 107 Dyslipidemia - Dormant Projects 289 Dyslipidemia - Discontinued Products 306 Dyslipidemia - Product Development Milestones 312 Appendix 324

List of Tables Number of Products under Development for Dyslipidemia, H2 2016 22 Number of Products under Development for Dyslipidemia - Comparative Analysis, H2 2016 23 Number of Products under Development by Companies, H2 2016 25 Number of Products under Development by Companies, H2 2016 (Contd..1) 26 Number of Products under Development by Companies, H2 2016 (Contd..2) 27 Number of Products under Development by Companies, H2 2016 (Contd..3) 28 Number of Products under Investigation by Universities/Institutes, H2 2016 29 Comparative Analysis by Late Stage Development, H2 2016 30 Comparative Analysis by Clinical Stage Development, H2 2016 31 Comparative Analysis by Early Stage Development, H2 2016 32 Comparative Analysis by Unknown Stage Development, H2 2016 33 Products under Development by Companies, H2 2016 34 Products under Development by Companies, H2 2016 (Contd..1) 35 Products under Development by Companies, H2 2016 (Contd..2) 36 Products under Development by Companies, H2 2016 (Contd..3) 37 Products under Development by Companies, H2 2016 (Contd..4) 38 Products under Development by Companies, H2 2016 (Contd..5) 39 Products under Development by Companies, H2 2016 (Contd..6) 40 Products under Development by Companies, H2 2016 (Contd..7) 41 Products under Investigation by Universities/Institutes, H2 2016 42 Dyslipidemia - Pipeline by Acasti Pharma Inc., H2 2016 43 Dyslipidemia - Pipeline by AFFiRiS AG, H2 2016 44 Dyslipidemia - Pipeline by Akcea Therapeutics Inc, H2 2016 45 Dyslipidemia - Pipeline by Allergan Plc, H2 2016 46 Dyslipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 47 Dyslipidemia - Pipeline by Amgen Inc., H2 2016 48 Dyslipidemia - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 49 Dyslipidemia - Pipeline by AstraZeneca Plc, H2 2016 50 Dyslipidemia - Pipeline by BASF SE, H2 2016 51 Dyslipidemia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016 52 Dyslipidemia - Pipeline by BioRestorative Therapies, Inc., H2 2016 53 Dyslipidemia - Pipeline by Cadila Pharmaceuticals Limited, H2 2016 54 Dyslipidemia - Pipeline by Cardax, Inc., H2 2016 55 Dyslipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2016 56 Dyslipidemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2016 57 Dyslipidemia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 58 Dyslipidemia - Pipeline by CJ HealthCare Corp., H2 2016 59 Dyslipidemia - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 60 Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H2 2016 61 Dyslipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 62 Dyslipidemia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 63 Dyslipidemia - Pipeline by Debiopharm International SA , H2 2016 64 Dyslipidemia - Pipeline by Eli Lilly and Company, H2 2016 65 Dyslipidemia - Pipeline by Esperion Therapeutics, Inc., H2 2016 66 Dyslipidemia - Pipeline by Gemphire Therapeutics Inc., H2 2016 67 Dyslipidemia - Pipeline by GlaxoSmithKline Plc, H2 2016 68 Dyslipidemia - Pipeline by Golden Biotechnology Corp., H2 2016 69 Dyslipidemia - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 70 Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 71 Dyslipidemia - Pipeline by Huons Co., Ltd., H2 2016 72 Dyslipidemia - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 73 Dyslipidemia - Pipeline by Innovent Biologics, Inc., H2 2016 74 Dyslipidemia - Pipeline by IPCA Laboratories Limited, H2 2016 75 Dyslipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 76 Dyslipidemia - Pipeline by Jenrin Discovery, Inc., H2 2016 77 Dyslipidemia - Pipeline by JW Pharmaceutical Corporation, H2 2016 78 Dyslipidemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 79 Dyslipidemia - Pipeline by Kotobuki Pharmaceutical Co., Ltd., H2 2016 80 Dyslipidemia - Pipeline by Kowa Company, Ltd., H2 2016 81 Dyslipidemia - Pipeline by Kymab Limited, H2 2016 82 Dyslipidemia - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 83 Dyslipidemia - Pipeline by LG Life Science LTD., H2 2016 84 Dyslipidemia - Pipeline by Lipicard Technologies Limited, H2 2016 85 Dyslipidemia - Pipeline by Lipigon Pharmaceuticals AB, H2 2016 86 Dyslipidemia - Pipeline by LipimetiX Development Inc, H2 2016 87 Dyslipidemia - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016 88 Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 89 Dyslipidemia - Pipeline by Merck & Co., Inc., H2 2016 90 Dyslipidemia - Pipeline by Nimbus Therapeutics, LLC, H2 2016 91 Dyslipidemia - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016 92 Dyslipidemia - Pipeline by Omeros Corporation, H2 2016 93 Dyslipidemia - Pipeline by Pfizer Inc., H2 2016 94 Dyslipidemia - Pipeline by Pharmena SA, H2 2016 95 Dyslipidemia - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 96 Dyslipidemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 97 Dyslipidemia - Pipeline by Sancilio & Company, Inc., H2 2016 98 Dyslipidemia - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 99 Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2016 100 Dyslipidemia - Pipeline by Torrent Pharmaceuticals Limited, H2 2016 101 Dyslipidemia - Pipeline by Yuhan Corporation, H2 2016 102 Dyslipidemia - Pipeline by Zydus Cadila Healthcare Limited, H2 2016 103 Assessment by Monotherapy Products, H2 2016 104 Assessment by Combination Products, H2 2016 105 Number of Products by Stage and Target, H2 2016 107 Number of Products by Stage and Mechanism of Action, H2 2016 112 Number of Products by Stage and Route of Administration, H2 2016 118 Number of Products by Stage and Molecule Type, H2 2016 120 Dyslipidemia - Dormant Projects, H2 2016 303 Dyslipidemia - Dormant Projects (Contd..1), H2 2016 304 Dyslipidemia - Dormant Projects (Contd..2), H2 2016 305 Dyslipidemia - Dormant Projects (Contd..3), H2 2016 306 Dyslipidemia - Dormant Projects (Contd..4), H2 2016 307 Dyslipidemia - Dormant Projects (Contd..5), H2 2016 308 Dyslipidemia - Dormant Projects (Contd..6), H2 2016 309 Dyslipidemia - Dormant Projects (Contd..7), H2 2016 310 Dyslipidemia - Dormant Projects (Contd..8), H2 2016 311 Dyslipidemia - Dormant Projects (Contd..9), H2 2016 312 Dyslipidemia - Dormant Projects (Contd..10), H2 2016 313 Dyslipidemia - Dormant Projects (Contd..11), H2 2016 314 Dyslipidemia - Dormant Projects (Contd..12), H2 2016 315 Dyslipidemia - Dormant Projects (Contd..13), H2 2016 316 Dyslipidemia - Dormant Projects (Contd..14), H2 2016 317 Dyslipidemia - Dormant Projects (Contd..15), H2 2016 318 Dyslipidemia - Dormant Projects (Contd..16), H2 2016 319 Dyslipidemia - Discontinued Products, H2 2016 320 Dyslipidemia - Discontinued Products (Contd..1), H2 2016 321 Dyslipidemia - Discontinued Products (Contd..2), H2 2016 322 Dyslipidemia - Discontinued Products (Contd..3), H2 2016 323 Dyslipidemia - Discontinued Products (Contd..4), H2 2016 324 Dyslipidemia - Discontinued Products (Contd..5), H2 2016 325


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports